SCHEMBL23093828

SCHEMBL23093828

Cc1nc(C2CCOCC2)n2c1cnc1ccc(-c3ccc(N4CCC(N(C)C)CC4)c(F)c3)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKDC P78527 16/20 0.59
▸ PIK3CB P42338 12/20 0.59
▸ ATR Q13535 12/20 0.59
▸ ATRIP Q8WXE1 12/20 0.59
▸ ATM Q13315 10/20 0.59
▸ MTOR P42345 3/20 0.59
▸ PIK3CD O00329 2/20 0.40
▸ CSF1R P07333 2/20 0.40
▸ CDK4 P11802 2/20 0.40
▸ CDK6 Q00534 2/20 0.40
▸ AXL P30530 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ CCNK O75909 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CCNH P51946 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ CDK5R1 Q15078 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23093843 0.91 PRKDC (0.58) PRKDCPIK3CBATRATRIPATM
SCHEMBL31338381 0.90 PRKDC (0.57) PRKDCPIK3CBATRATRIPATM
SCHEMBL21541787 0.86 PRKDC (0.61) PRKDCPIK3CBATRATRIPATM
SCHEMBL23093831 0.83 ATM (0.42) PRKDCPIK3CBATRATRIPATM
SCHEMBL23119185 0.81 ATM (0.39) PRKDCPIK3CBATRATRIPATM
SCHEMBL29688063 0.81 ATM (0.39) PRKDCPIK3CBATRATRIPATM
SCHEMBL23093855 0.81 PRKDC (0.58) PRKDCPIK3CBATRATRIPATM
SCHEMBL23093880 0.80 PRKDC (0.57) PRKDCPIK3CBATRATRIPATM
SCHEMBL21541755 0.79 PRKDC (0.65) PRKDCPIK3CBATRATRIPATM
SCHEMBL23093864 0.78 PRKDC (0.55) PRKDCPIK3CBATRATRIPATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220354859-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-11-10 — — US claimed
EP-4028400-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-07-20 — — EP claimed
WO-2021047646-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF IMPACT THERAPEUTICS, INC (CN) 2021-03-18 — — WO claimed
CN-119215050-A Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs 上海瑛派药业有限公司 2024-12-31 — — CN disclosed
CN-119080781-A Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-12-06 — — CN disclosed
CN-114787162-B Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-09-03 — — CN disclosed
US-20220354859-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-11-10 — — US disclosed
CN-114787162-A Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2022-07-22 — — CN disclosed
EP-4028400-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-07-20 — — EP disclosed
WO-2021047646-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF IMPACT THERAPEUTICS, INC (CN) 2021-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354859-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF CHEK2, CHEK1, ATM PRKDC 26/4885PIK3CB 214/4885ATR 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback